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The role of non-invasive nocturnal domiciliary ventilation (NNV) in chronic obstructive pulmonary disease (COPD) 
patients with chronic hypercapnia is still discussed. The aims of this study were to evaluate the long-term survival, 
the clinical effectiveness and side-effects of NNV in these patients. 
Forty-nine stable hypercapnic COPD patients on long-term oxygen therapy (LTOT) were assigned to two groups: 
in Group 1, 28 patients performed NNV by pressure support modality in addition to LTOT; in Group 2, 21 patients 
continued their usual LTOT regimen. Treatment was assigned according to the compliance to NNV, after an in 
hospital period. Mortality rate, hospital stay (HS) and ICU admissions (IA) were recorded in the two groups. HS 
and IA were compared to those recorded in a similar period of follow-back. Lung and respiratory muscle function, 
dyspnoea, and exercise capacity (by 6-min walk test) were evaluated baseline and every 3-6 months up to 3 yr. 
Mean follow-up time was 35 f 7 months. Mortality rate was not different between the two groups: 16, 33, 46% 
and 13, 28, 50% at 1, 2 and 3 yr in Groups 1 and 2 respectively. Lung and respiratory muscle function did not 
significantly change over time. A significant increase in 6-min walk test (from 245 * 78 to 250 It 88, 291 & 75, 
284 ZIZ 89 m after 1, 2 and 3 yr respectively, PcO.01) was observed only in patients undergoing NNV. In comparison 
to the follow back HS significantly decreased in both groups (from 37 & 29 to 15 & 12 and from 32 + 18 to 17 & 11 
days/pt/yr in Groups 1 and 2 respectively, P<O.OOl) whereas IA significantly decreased only in patients performing 
also NNV (from 1.0 rt 0.7 to 0.2 f 0,3/pt/yr, P<O.OOOl). 
Addition of NNV by pressure support modality to LTOT does not improve long term survival but significantly 
reduces ICU admissions and improves exercise capacity in severe COPD with hypercapnia. 
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Introduction 
Long term oxygen therapy (LTOT) has been shown to 
improve survival in hypoxaemic patients with chronic 
obstructive pulmonary disease (COPD) independent of the 
presence of chronic hypercapnia (1,2). Long term mech- 
anical ventilation has been proposed (336) in addition to 
LTOT in COPD patients able to spontaneously breath with 
the theoretical rationale: to unload the ventilatory muscles 
(7,8), to improve gas exchange (9), to reset the respiratory 
central drive (10). It is usually delivered by either standard 
volume-cycled ventilators in assisted/controlled (A/C) mode 
or by pressure support ventilation (PSV). 
Physiological studies have shown that non-invasive 
positive pressure ventilation (NIPPV) may unload the 
diaphragm in stable COPD (7,s) while some clinical studies 
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suggested that non-invasive nocturnal ventilation (NNV) 
could be associated with daytime arterial blood gas 
improvement, and reduced hospitalisation and need of 
tracheotomy (5,6). While NIPPV has been gaining increas- 
ing popularity to reverse acute on chronic respiratory 
failure (11) and in the management of chronic respiratory 
failure resulting from neuromuscular and restrictive chest 
wall diseases (12), controlled trials in stable COPD patients 
report conflicting results on short-term, clinical and func- 
tional outcome (13-15). Even fewer data are reported on 
long-term effects (5,16,17). In a previous study over 
18 months we showed that NIPPV per se was not able to 
improve survival in these patients (17) in comparison to 
LTOT alone. 
The aims of this study were therefore: (i) to assess the 
long term survival, (ii) to evaluate the clinical and func- 
tional outcomes and (iii) to report the treatment compliance 
and side-effects of chronically hypoxaemic and hypercapnia 
COPD patients undergoing addition of NIPPV by means of 
PSV to LTOT in comparison with a control group of 
COPD patients undergoing LTOT alone. 
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Methods 
The study was approved by the Ethical Committees of 
Medical Centre of Gussago, S. Maugeri Foundation, and 
Azienda Ospedaliera C. Poma, Mantova, Italy. The study 
was conducted according to the declaration of Helsinki. 
Patients gave their informed consent to participate in the 
study. 
PATIENTS 
Forty-nine severe COPD patients defined by the American 
Thoracic Society (ATS) guidelines (18) were recruited from 
December 1991 to December 1994. All patients were 
ex-smokers, met the criteria for LTOT (19) and had been on 
oxygen for at least 12 months. At the time of the study the 
patients had to be free from exacerbations. Prior to and 
during the study, all of them received regular treatment 
(18-20); no change in medical and oxygen therapy was 
made the month preceding the inclusion in the study. 
Thirty-five patients had previously experienced the use of 
nasal PSV during an exacerbation over the last 2 yr. 
At hospital admission, all the following inclusion criteria 
had to be met: (1) stable clinical state i.e. stability in blood 
gas values and pH (>7.35), and lack of exacerbation in the 
preceding four weeks; (2) PaO, ~8 kPa and PaCO, >6 kPa 
respectively, during spontaneous breathing room air at the 
time of the study; (3) at least one ICU admission due to 
severe exacerbation in the two years preceding the study; (4) 
evidence of family support or availability of a care-giver at 
home; and (5) geographical allocation allowing the patients 
to easily reach the hospital. Patients with other organ 
failure, cancer and inability to cooperate in long-term trials 
were excluded. Patients were also excluded if they had a 
12% or more than 200 ml increase in FEV, after admin- 
istration of an inhaled bronchodilator, or a suspicion of 
sleep apnoea as assessed by nocturnal monitoring of arterial 
oxygen saturation (SaO,) (21). 
FUNCTIONAL MEASUREMENTS 
Lung volumes and forced vital capacity (FVC) were 
measured by means of a volume constant body plethysmo- 
graph (1085 Medical Graphic Corp, St. Paul MN, U.S.A.). 
The predicted values according to Quanjer (22) were used. 
Arterial blood gases were assessed at baseline and every 
3 months. PaO,, PaCO,, and pH were measured by 
means of an automated analyser (ABL 500, Radiometer, 
Copenhagen, Denmark) on blood samples taken from 
radial artery while patients in the sitting position were 
breathing room air for at least 1 h. Diffusing capacity for 
carbon monoxide (DLCO) was determined by the single- 
breath method Medical Graphic Corp. St. Paul, MN, 
U.S.A.). SaO, was monitored by pulse oximetry by means 
of a portable recorder with a memory chart (Pulsox 5, 
Minolta, Osaka, Japan). The inspiratory muscle strength 
was assessed by measuring’the maximal inspiratory pres- 
sure (MIP) at the level of functional residual capacity 
(FRC) according to the method of Black & Hyatt (23) using 
a respiratory module system (Medical Graphic Corp, 
St. Paul, MN, U.S.A.). Each patient performed a minimum 
of five MIP manoeuvres with at least 1 min interval between 
efforts until two acceptable values not differing from each 
other by more than 5% were obtained. The best value was 
recorded. Dyspnoea sensation was assessed at baseline and 
every 6 months according to the ATS scale (24). Subjective 
rating of dyspnoea under NIPPV trial was performed by 
means of a visual analogue scale (VAS) (26). 
Exercise capacity was evaluated by means of the 6-min 
walk test (25), at admission and every 12 months. A 
baseline 6-min walk test was performed with three practice 
tests in two consecutive days. The highest value was 
recorded. A single measurement was performed during the 
follow-up. The 6-min walk test measurements were per- 
formed and recorded under the supervision of a nurse not 
involved in the study. 
CLINICAL OUTCOME 
Days of hospital stay (HS), number of events (in particular 
need of endotracheal intubation) of ICU admissions (IA) 
were recorded by hospital registers, interviewing relatives or 
the general practitioner and comparing the follow-up 
period to a similar period before entering the study (follow- 
back). In all cases IA was defined as hospitalisation due to 
severe exacerbation leading to acute respiratory failure and 
needing ventilatory assistance (either invasively or non 
invasively). Endotracheal intubation (EI) was decided by 
the attending physicians in ICUs (also of different 
Hospitals) unaware of the study. Criteria of endotracheal 
intubation were those commonly used in the clinical prac- 
tice in the ICUs in Italy. The days spent in the hospital, 
when in stable state, for NNV training were not taken into 
account. Finally, mortality rate was recorded in the 
follow-up in both groups. 
PROTOCOL 
Patients were divided into two groups: Group 1 performed 
both LTOT and NNV, Group 2 performed LTOT alone. 
The assignment was not random. All the patients meeting 
the inclusion criteria performed an in-hospital trial of NNV 
(see below) spending at least 15 days in the hospital. The 
effectiveness of NIPPV was assessed by means of evaluation 
of arterial blood gases and dyspnoea (by VAS) during 1 h 
of continuous ventilation. After two daily practice trials in 
which effects of NIPPV were tested, patients were 
instructed to perform non-invasive ventilation for at least 
five consecutive hours at night. At the end of this period 
patients were divided in the two groups according to the 
compliance to the ventilator treatment: they were allocated 
in the LTOT group if they showed no compliance to NNV 
or refused it. Lack of compliance was defined according 
to the patient’s inability to use properly (subjective 
intolerance, excessive air leaks) the ventilatory device for 
the scheduled 5 h/night even on one night during the trial. 
No specific rehabilitation program was provided for either 
group during the follow-up period. When necessary, 
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changes in medical therapy of each patient were prescribed 
by physicians of our departments or by his/her general 
practitioner who was instructed to communicate to our 
departments. 
VENTILATORY ASSISTANCE 
Pressure support ventilation was delivered through a com- 
mercial nasal mask (Respironics, Murrysville, PA, U.S.A.) 
by means of a portable ventilator able to compensate for 
leaks (BiPAP, Respironics, Murrysville, PA, U.S.A.) (9,27). 
The ventilatory device was set during the daily practice 
attempt by an attending physician unaware of the study 
with the minimal inspiratory positive airway pressure 
(IPAP) able to achieve an expiratory tidal volume >8 ml/kg 
was considered as the normal reference value (IPAP ranged 
from 10 to 16 cm H,O). The expiratory positive airway 
pressure (EPAP) was set in order not to overcome the 
supposed intrinsic positive expiratory pressure (PEEPi) of 
these stable patients (28) and ranged from 2 to 4 cm H,O. 
Spontaneous-time mode with the adopted pressure support 
device was set with a back up respiratory frequency of 
10 bpm. Patients of both groups continued LTOT as pre- 
viously prescribed. In Group 1, supplemental oxygen dur- 
ing NNV was administered via a cannula attached to a 
side-port of the nasal mask at a FiO, able to achieve a 
baseline SaO, >92% which was also the target value for 
Group 2. 
TREATMENT COMPLIANCE 
Compliance to LTOT was assessed in the follow-up by 
measuring the weekly use and by interviewing the patients 
and their relatives. The time patients used the ventilator at 
home was assessed by interviewing them and their relatives 
and by controlling the device time-counter. Side effects due 
to the prolonged use of both oxygen and NNV were also 
recorded in the follow-up. 
STATISTICS 
Data are shown as mean ic SD. Differences within and 
between groups were tested by means of analysis of vari- 
ance (ANOVA) with repeated measures. Post hoc analysis 
was performed when requested by ANOVA. A P value of 
less than 0.05 was considered to be statistically significant. 
Mortality was described by the Kaplan-Meier survivor 
analysis and the significance of differences in survival 
between groups were tested by log-rank test. Differences 
in frequency distribution were tested by means of x2 
analysis. 
Results 
Twenty-one of the 49 patients (43%) were not compliant 
with or refused NNV, and were included in the control 
group (Group 2). Demographic, anthropometric and func- 
tional characteristics of patients in study are shown in 
TABLE 1. Demographic, anthropometric and functional 
characteristics of patients in study 
Group 1 Group 2 P 
Patients (n) 
M/F 
Age 64 
BMI 
Length of disease (yr) 
FEV, (%pred) 
FVC (%pred) 
RV (%pred) 
FEV,/FVC(%) 
DLCO (%pred) 
MIP (cmH,O) 
PaCO, (kPa)* 
PaO, (kPa)* 
Hospital admissions (nlptlyr) 
28 
2216 
66 i 6 
23 &4 
9+2 
31 rt8 
57zt9 
154*24 
46+ 15 
43* 13 
42+11 
7.0 zk 0.6 
6.5 rt 0.9 
2.0 f 0.6 
21 
1417 
66 i 8 
23 f 1 
9zlc3 
32 zk 10 
57 dc 7 
159&44 
47+9 
47 k 8 
45+9 
6.8 zt 0.6 
6.4 & 1.0 
1.9 f 0.4 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
*Breathing room air. 
Table 1. The two groups were not different for anthropo- 
metric and functional characteristics: they suffered from 
similar severity of airway obstruction and hyperinflation. 
Previous smoking habit and medical therapy did not differ 
between the two groups. 12 patients (six in each group) 
were on long-term B2-agonists and five patients (three in 
Group, 1 and two in Group 2), were taking oral theo- 
phylline. Number of patients who experienced NIPPV 
during acute exacerbation over 2 yr prior the study (20/28 
and 14/21 patients in Groups 1 and 2 respectively) and the 
rate of related endotracheal intubation (5/20 and 3/14 
patients in Groups 1 and 2 respectively) were similar in 
both groups. 
An inverse significant relationship (Y= - 0.62; P<O.OOOl) 
was found between baseline PaCO, and GPaCO, under 
NIPPV. The practice daily attempts of NIPPV resulted in a 
mean 8% decrease in PaCO, in comparison with baseline 
level (9 and 6% decrease in Groups 1 and 2 respectively). 
All the patients of Group 1 and 18 out of 21 (85%) patients 
of Group 2 showed a decrease from the baseline PaCO, 
value: x2 analysis showed that this difference was not 
significant. NIPPV resulted in improvement in dyspnoea as 
assessed by VAS ( - 23 rt 12% and - 16 * 20% in Groups 1 
and 2 respectively). 
Mean duration of follow-up was 35 Z!Z 7 months. In Fig. 1 
the survival rates of the two groups evaluated by Kaplan- 
Meier analysis are shown. Mortality rate was not different 
between groups at any time (16, 33,46% and 13,28, 50% at 
1, 2 and 3 yr in Groups 1 and 2 respectively. 
In either group dynamic lung volumes, MIP and arterial 
blood gases did not significantly change over time. These 
parameters did not differ between groups at any time up to 
3 yr. In Table 2 time course of arterial blood gases during 
the follow-up is shown. Dyspnoea sensation (Fig. 2) did not 
change over time in either group. The walked distance 
significantly increased (from 245 & 78 to 250 & 88,291 & 75, 
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FIG. 1. Survival curves by Kaplan-Meier model in the 
studied population. No significant differences were found 
between groups. ~ - -, Group 1; -, Group 2. 
284 & 89 m after 1, 2 and 3 yr respectively, P<O.Ol) in NNV 
group, but not in Group 2 (Fig. 2). 
In comparison with the follow back HS significantly 
decreased in both groups (from 37 i 29 to 15 & 12 and from 
32 * 18 to 17 * 11 dayslptlyr in Groups 1 and 2 respect- 
ively) whereas the rate of IA significantly decreased only in 
patients performing also NNV (from 1.0 ?C 0.7 to 0.2 * 0.3 
and from 1.2 + 0.4 to 0.9 & 0,3/pt/yr in Groups 1 and 2 
respectively) (Fig. 3). The need for endotracheal intubation 
was significantly less in the NNV group (0.1 -+ 0.1 vs. 
0.5 & 0.3 in Groups 1 and 2 respectively; P~0.05). 
The use of NNV in Group 1 was 7.4 * 1.3 h/night. 
Compliance to LTOT in the follow-up was 18.5 & 2.1 and 
19.0 Ifi 1.8 h/day in Groups 1 and 2 respectively. The side 
effects of NNV shown in Table 3 did not require any 
discontinuation of NNV. One patient temporarily changed 
the nasal mask to an Adam type due to a deep skin lesion of 
the bridge of the nose. No side effects attributable to LTOT 
were recorded in either group. 
Discussion 
This study indicates that, in comparison to LTOT alone, 
the addition of NNV by PSV does not improve 3 yr survival 
but is able to increase the exercise tolerance and to reduce 
the rate of admission and endotracheal intubation in the 
ICU of severe COPD patients with chronic hypercapnia. 
NIPPV has been gaining increasing popularity in the 
management of chronic respiratory failure. The benefit is 
more clearly demonstrated for chronic respiratory failure 
consequent upon non-obstructive conditions than for 
patients with COPD (10,12,16). Indeed results in COPD 
patients with hypercapnia are still discussed (13-15). Dif- 
ferences in patient selection (13-15) or in ventilation 
modalities (29), may explain different results. In this study 
PSV was used. This modality of ventilation is considered to 
be well tolerated for an overnight delivery on COPD 
patients (13,30,31) and compliance to the machine increases 
with prolonged use (32). The rate of refusal to the ventilator 
(43%) was similar to our previous experience on similar 
patients (17). Goldstein et al. (32) also found a difficult 
initial coping to the ventilator in 56% of in COPD 
patients. 
The practice daily attempts of NIPPV resulted in a mean 
8% decrease in PaCO, in comparison with baseline level in 
most of the patients and only three patients of Group 2 did 
not show any PaCO, improvement after 1 h: a relationship 
existed between benefit (in terms of PaCO, decrease) from 
NIPPV during practical attempt and the higher PaCO, 
value at baseline, however it was the same in both groups. 
The lack of significant difference in all baseline characteris- 
tics between the two groups is surprising and may suggest 
that other factors not specifically assessed in this study like 
psychological factors (e.g. claustrophobia), home environ- 
mental facilities, etc., may have influenced the compliance 
rate to NNV. 
Survival proportion obtained from the Kaplan-Meier 
model in the two groups was similar (see Fig. 1) suggesting 
that NNV per se is not able to influence this outcome. 
The observed survival was also similar to that reported 
TABLE 2. Time course of arterial blood gases 
Basal Year 1 Year 2 Year 3 (AN&A) 
PH 
Group 1 
Group 2 
*PaCO, kPa 
Group 1 
Group 2 
PaO, kPa 
Group 1 
Group 2 
7.37 * 0.03 7.37 f 0.02 7.38 =k 0.03 7.38 zk 0.02 ns. 
7.38 =t 0.02 7.38 zt 0.02 7.38 zt 0.01 7.38 2~ 0.01 n.s. 
7.0 3~ 0.6 6.9 f 0.8 6.9 + 1.1 6.8 + 1.2 n.s. 
6.8 zk 0.6 6.5 YII 0.5 6.6 i 0.8 6.7 zt 1.1 n.s. 
6.5 f 0.9 6.5 i 0.9 6.9 f 0.5 6.8 It 0.4 n.s. 
6.4 zt 1.1 6.5 =t 0.5 6.8 * 0.4 6.6 * 0.4 n.s. 
No differences between groups at any time. 
*Breathing room air. 
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FIG. 2. Changes in ATS dyspnoea score (a) and in exercise tolerance (b) in the two study groups over the period of 3 yr. 
+, Group 1; n , Group 2. *P<O.Ol between groups; tPcO.01 among times. 
in COPD with chronic insufficiency undergoing LTOT 
(la 
In our study lung volumes and arterial blood gases did 
not change over time in either group. At difference with 
our study, Meecham-Jones et al. (14) found that diurnal 
PaO, and PaCO, significantly improved over a 3 month 
nocturnal non-invasive PSV. The range of IPAP of our 
study is slightly lower than used by Meecham- Jones et al. 
(14), but is similar to values reported by Lin (15) and by 
Gay et al. (33) two studies showing no significant effect of 
NNV in COPD patients. Strumpf et al. (13) with a IPAP 
adjusted to match patients’ spontaneous breathing rate and 
to provide a 20-50X increase in resting minute ventilation 
and a reduction of at least 5 mmHg in end tidal PCO, 
(mean IPAP: 15 cm H,O) did not show any change in 
arterial blood gases in a 3-month study. Values of IPAP like 
those used in our study have been shown to be able to 
reduce the electromyographic and mechanical activity of 
the diaphragm in stable hypercapnia COPD patients (7-9). 
Whether the difference with the study by Meecham-Jones 
et al. (14) has to be ascribed to the lower levels of IPAP 
used in our study remains to be elucidated. The proposed 
mechanism by which NNV may produce changes in respir- 
atory function and/or diurnal blood gases in such patients 
remains controversial. In our patients undergoing NNV 
PaCO, showed a slight although not significant trend 
toward improvement over time (see Table 2). The lack of 
statistical significance may well be due to the relatively 
small sample size; nevertheless a lack of worsening in 
PaCO, all over a 3-yr period in patients on LTOT has been 
previously reported (34). Chronic hypercapnia may be 
considered as a consequence of a breathing pattern adopted 
as a means to unload respiratory muscles in COPD patients 
(35) although the rate of deterioration over time in PaCO, 
was found to be related to the necessity of ICU admissions 
(34). The hypothesis that chronic respiratory muscle fatigue 
could play a role in chronic CO, retention was not con- 
firmed (36) and the role of intermittent rest of loaded 
respiratory muscles as one of the possible mechanisms 
through which NNV can improve daytime arterial blood 
gases and symptoms is still questioned (5). Elliott et al. (6) 
found no relationship between slight changes in MIP and 
changes in PaCO, in COPD patients undergoing NNV by 
means of volume-cycled ventilators. Also of interest is a 
randomised study of NIPPV versus sham in COPD (33). 
Patients in the active limb received inspiratory positive 
pressure of up to 10 cm H,O; those in the sham limb 
received inspiratory pressure at the lowest possible level. 
No overnight monitoring of SaO, and PaCO, was carried 
out. Results showed that NIPPV offered no improvement in 
arterial blood gas tensions, sleep efficiency and exercise 
tolerance over the sham group. In our study forced lung 
volumes (as expressed as % of predicted) remained 
unchanged despite the use of NNV, this is in agreement 
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FIG. 3. Comparison of hospital stay (a) and ICU admissions (b) in NNV (Group 1) and LTOT (Group 2) patient 
between follow-up (a) and follow-back (0) periods. n.s. between groups at baseline (follow-back); WO.0001 between 
groups for IA (follow-up), “WO.001; tP<O.OOOl (between times). 
with previous studies over shorter follow-up (6,16,17). 
Deterioration of lung volumes in COPD is expected over 
years (37,38), nevertheless the lack of significance over 3-yr 
changes in FEV, (from, 895 + 310 to 830 + 303 and from 
855 rt 304 to 744 * 202 ml in Groups 1 and 2 respectively), 
as in the present study, may be due to the low baseline 
absolute values at the beginning of the study. 
In our study the result improvement in the 6-min walk 
test only in patients under NNV (Fig. 2, bottom) might be 
ascribed to a learning or a motivation effect. In particular, 
the different methodology assessed to test the 6-min walk 
during the follow-up (one test compared to three tests on 
two consecutive days at baseline) could have favoured only 
the most motivated and compliant patients. However, the 
operator performing the tests during the follow-up was not 
involved in the study as the 6-min walk test is a routine 
measurement we perform in our outpatients. Indeed, 
another measurement prone to be influenced by motivation 
and learning that is MIP did not improve in either group. 
Indeed at variance with our previous report (17), we failed 
to demonstrate any significant improvement in MIP in the 
TABLE 3. Side effects associated with NIPPV 
n % 
Nasal skin lesion 6 21 
Gastric distension 4 14 
Rhinorrhea 4 14 
Mucosal dryness 2 7 
Skin inflammation 1 4 
None 11 40 
ventilated group. Previous studies (12,14) showed no 
improvement in MIP in COPD patients using NNV. The 
longer duration of the present study could have balanced 
the effect of shorter observation in respiratory muscle 
strength. Dyspnoea sensation was unchanged over time in 
both groups (Fig. 2, top). In short (8) and medium-term 
(13) trials of NNV in COPD, dyspnoea measurements 
showed conflicting results. Our results could have bee 
influenced by the kind of scale we used. Indeed dyspnoea 
scale of the ATS may not prove to be the ideal indicator of 
therapy response as other (i.e. Borg or visual analogue 
scale) because of its narrow range (24). 
The main positive clinical result in this study was the 
significant decrease in the rate of IA compared to the 
follow-back period observed only in NNV patients (Fig. 3). 
This observation is in agreement with our previous prelimi- 
nary study (17): at variance with that experience, in this 
study patients of both groups were initially similar for the 
clinical severity and the number of hospitalisations. Never- 
theless, HS significantly decreased in both groups (Fig. 3). 
Indeed, the reduction in hospital stay of both groups may 
be due to the increased follow-up period. Other studies (3,5) 
suggested a reduction in number of hospitalisations of 
ventilated COPD over a period of 2 yr indicating a possible 
cost saving effect. Our study, confirming our previous 
results (17), is the first to show an improvement in the 
quality of hospitalisation (reduction in IA and endotracheal 
intubation rate) in severe COPD under NNV over a period 
of more than 2 yr. This result deserves a comment. Due to 
the historical way to collect information on IA, this results 
could be considered as a soft outcome measure. Neverthe- 
less, decision for admitting and treating patients in the 
ICUs was taken by physicians not aware of the study. It can 
be argued that it is possible that there was a lower threshold 
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for admitting LTOT patients to the ICUs whereas patients 
on NNV where deemed not to need it because they were 
already receiving ventilatory support. Due to this consid- 
eration we cannot speculate that NNV has improved patho- 
physiological condition so to reduce the ‘physiological’ 
need of IA. However, independently of the mechanism 
underlying this result, as a matter of fact the use of NNV 
resulted in a lower rate of endotracheal intubation and 
related life threatening complications (39). 
In Group 1, NNV was used 7.4 5 1.3 h/night and it was 
associated with side effects in most of patients (Table 3) but 
none of them had to discontinue the treatment. The long 
night use of NNV is not surprising: indeed Goldstein et al. 
(32) found in six out of nine COPD patients selectively used 
NIPPV during the night and the mean duration of use 
in patients including COPD was 9 & 2 h/day. Side effects 
are comparable with those of Meecham-Jones et al. (42): 
also in that study the major problem was the skin 
abrasion/ulceration over the nasal bridge. 
Our study was prospective, without limitations of an 
historical comparison (40) nevertheless it has some import- 
ant limitations. The patients were not randomised and 
controls were selected according to the compliance/refusal 
to the ventilator: therefore, we cannot exclude that a better 
clinical outcome was observed in the most motivated 
patients. The sample size is small, without the power 
necessary to detect differences between groups in outcome 
measures: an analysis to define a priori primary outcome 
measures was not performed. With these limitations and 
although the reduced rate of IA and endotracheal intuba- 
tion may be very useful, our data on survival do not justify 
a generalised use of NNV by pressure ventilators in stable 
hypercapnia COPD. Encouraging results are coming from 
the preliminary results of a large prospective and random- 
ised European multicentre study performed using volume- 
cycled ventilators and nasal industrial masks. In that study, 
the first actuarial survival analysis showed a trend towards 
a positive impact of NNV which at the moment of 
observation did not reach statistical significance (41). 
In conclusion, the addition of NNV to LTOT in com- 
pliant COPD patients with chronic hypercapnia does not 
improve survival but significantly reduces ICU admissions 
and slightly improves exercise capacity, prompting the need 
for further randomised studies. 
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